Jibeier Pharmaceutical: Results of Phase III Clinical Trial for New Antidepressant JJH201501 Released

Zhitong
2025.10.30 08:45

Jibeier Pharmaceutical announced that the new antidepressant JJH201501 currently under development has completed Phase III clinical trials. The trial employed a randomized, double-blind, placebo-controlled, multi-center design, with four groups: a 10mg trial drug group, a 15mg trial drug group, a placebo group, and a positive control group. Each of the 10mg trial drug group, 15mg trial drug group, and placebo group included 150 subjects, while the positive control group included 75 subjects, totaling 525 subjects who underwent an 8-week double-blind trial. The results showed that after 8 weeks of continuous administration, the clinical efficacy of the 10mg and 15mg JJH201501 tablet groups in treating depression was significantly better than that of the placebo group, with statistical significance, and comparable to the 20mg group of hydrobromide vortioxetine tablets

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.